

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-15. (Canceled)

16. (Previously Presented) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1, wherein the polypeptide consists of the polypeptide set forth in SEQ ID NO:2; and

(b) a physiologically acceptable carrier or excipient;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

17. (Canceled)

18. (Previously Presented) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient an immunogenic composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1, wherein the polypeptide consists of the polypeptide set forth in SEQ ID NO:2; and

(b) a non-specific immune response enhancer;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

19.-23. (Canceled)

24. (Previously Presented) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising, a WT1 polypeptide consisting of the polypeptide set forth in SEQ ID NO:2 and a physiologically acceptable carrier or excipient, thereby stimulating and/or expanding T cells in a mammal.

25.-49. (Canceled)

50. (Previously Presented) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient an immunogenic composition comprising:

(a) An isolated polypeptide comprising a WT1 polypeptide wherein the WT1 polypeptide consists of no more than amino acids 1-249 of WT1 and comprises the amino acid sequence set forth in SEQ ID NO:2; and

(b) a non-specific immune response enhancer, wherein the non-specific immune response enhancer preferentially enhances a CD8⁺ T cell response in a patient; and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

51. (Withdrawn) The method of claim 50, wherein the polypeptide consists of 4-16 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.

52. (Withdrawn) The method of claim 50, wherein the polypeptide consists of 8-10 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.

53.-55. (Canceled)

56. (Previously Presented) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient an immunogenic composition comprising:

(a) an isolated polypeptide comprising a WT1 polypeptide wherein the WT1 polypeptide comprises amino acids 1-249 of WT1 and wherein the WT1 polypeptide does not comprise full-length WT1;

(b) a non-specific immune response enhancer, wherein the non-specific immune response enhancer preferentially enhances a CD8⁺ T cell response in a patient;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.